



Eastland Medical  
Systems LTD

# ASX Release

## Eastland Clinical Trial Update

### May 2011

Eastland is pleased to provide an update on progress of the ArTiMist™ clinical trial.

Eastland received notification from the Directors of ProtoPharma Limited that the trials were progressing well and that, further to the 50 patients that have been treated in Rwanda, recruitment has now commenced in Burkina Faso. A further 50 are now being recruited for treatment under the Burkina Faso component of the trial and we are advised approval has also been received from Ghana.

As previously advised it is also planned to treat patients from both Tanzania and Uganda and approval is pending in both.

Eastland will provide further updates as soon as we receive them from our Licensor and Consultant ProtoPharma.

Eastland would like to direct our shareholders to the following article that was published in The Lancet Infectious Diseases, Volume 11, Issue 6, Pages 428 - 429, June 2011.

The article further supports the use of Artemisinin based therapy for the treatment of Malaria.

**From Quinine to Artesunate in Africa** by Talha Burki.

Abstract;

“An overwhelming body of evidence supports the superiority of artesunate over quinine for the treatment of severe malaria in adults and children across the world”, concludes *Making the Switch*, a new report by Médecins Sans Frontières (MSF) that calls on African countries to move from quinine to artesunate as quickly as possible. MSF estimates that switching to artesunate would save 195,000 lives every year.

**Further information:**

Stephen Carter  
Chief Executive Officer  
Director  
Eastland Medical Systems Ltd  
Tel: +61 8 6142 5555  
[sjcarter@eastlandmedical.com.au](mailto:sjcarter@eastlandmedical.com.au)

For personal use only

## Background

ProtoPharma are responsible for carrying out the clinical development of ArTiMist™, a sublingual malaria treatment for children with severe or complicated Falciparum Malaria, for the benefit of Eastland. The current trial is underway in Africa and is titled;

*A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.*

For personal use only